Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring
暂无分享,去创建一个
[1] Andreas Mühlemann,et al. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. , 2006, European journal of pharmacology.
[2] Markus H. J. Seifert. Assessing the Discriminatory Power of Scoring Functions for Virtual Screening , 2006, J. Chem. Inf. Model..
[3] Shay Bar-Haim,et al. G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[5] Tobias Noeske,et al. Allosteric Modulation of Family 3 GPCRs , 2006 .
[6] W. Spooren,et al. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. , 2001, Trends in pharmacological sciences.
[7] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[8] Didier Rognan,et al. High‐Throughput Modeling of Human G‐Protein Coupled Receptors: Amino Acid Sequence Alignment, Three‐Dimensional Model Building, and Receptor Library Screening. , 2004 .
[9] R. Horuk,et al. I want a new drug: G-protein-coupled receptors in drug development. , 2006, Drug discovery today.
[10] R. Wolf,et al. Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.
[11] N. Cosford,et al. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. , 2004, Journal of medicinal chemistry.
[12] W Patrick Walters,et al. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance , 2004, Proteins.
[13] I. Wilson,et al. Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors. , 2004, Journal of medicinal chemistry.
[14] Robin Taylor,et al. Comparing protein–ligand docking programs is difficult , 2005, Proteins.
[15] F. Gasparini,et al. The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.
[16] N. Cosford,et al. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. , 2004, Bioorganic & medicinal chemistry letters.
[17] Markus H. J. Seifert,et al. Virtual high-throughput screening of molecular databases. , 2007, Current opinion in drug discovery & development.
[18] C. Swanson,et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders , 2005, Nature Reviews Drug Discovery.
[19] Brian K. Kobilka,et al. High resolution crystal structure of human B2-adrenergic G protein-coupled receptor. , 2007 .
[20] Thomas Lengauer,et al. Flexible docking under pharmacophore type constraints , 2002, J. Comput. Aided Mol. Des..
[21] Frits Daeyaert,et al. A pharmacophore docking algorithm and its application to the cross‐docking of 18 HIV‐NNRTI's in their binding pockets , 2004, Proteins.
[22] Michal Vieth,et al. SDOCKER: a method utilizing existing X-ray structures to improve docking accuracy. , 2004, Journal of medicinal chemistry.
[23] Kenneth M. Johnson,et al. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. , 2006, Journal of medicinal chemistry.
[24] F. Gasparini,et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.
[25] Martin Ebeling,et al. An Automated System for the Analysis of G Protein-Coupled Receptor Transmembrane Binding Pockets: Alignment, Receptor-Based Pharmacophores, and Their Application , 2005, J. Chem. Inf. Model..
[26] Xueliang Fang,et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.
[27] X Fradera,et al. Similarity‐driven flexible ligand docking , 2000, Proteins.
[28] F. Gasparini,et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.
[29] Gisbert Schneider,et al. Searching for drug scaffolds with 3D pharmacophores and neural network ensembles. , 2007, Angewandte Chemie.
[30] Richard D. Taylor,et al. Virtual Screening Using Protein—Ligand Docking: Avoiding Artificial Enrichment. , 2004 .
[31] R. Osman,et al. Lactisole Interacts with the Transmembrane Domains of Human T1R3 to Inhibit Sweet Taste* , 2005, Journal of Biological Chemistry.
[32] Shaomeng Wang,et al. Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling. , 2006, Journal of medicinal chemistry.
[33] Roman Osman,et al. Identification of the Cyclamate Interaction Site within the Transmembrane Domain of the Human Sweet Taste Receptor Subunit T1R3*[boxs] , 2005, Journal of Biological Chemistry.
[34] Yael Marantz,et al. Modeling the 3D structure of GPCRs: advances and application to drug discovery. , 2003, Current opinion in drug discovery & development.
[35] Dehua Huang,et al. 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. , 2004, Bioorganic & medicinal chemistry letters.
[36] Jordi Mestres,et al. Guided docking approaches to structure-based design and screening. , 2004, Current topics in medicinal chemistry.
[37] Dehua Huang,et al. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. , 2004, Bioorganic & medicinal chemistry letters.
[38] J. Kew,et al. Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.
[39] D. J. Price,et al. Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.
[40] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.
[41] Peter L. Freddolino,et al. Prediction of structure and function of G protein-coupled receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[42] Li Xing,et al. Evaluation and application of multiple scoring functions for a virtual screening experiment , 2004, J. Comput. Aided Mol. Des..
[43] Peter Willett,et al. Knowledge-Based Interaction Fingerprint Scoring: A Simple Method for Improving the Effectiveness of Fast Scoring Functions , 2006, J. Chem. Inf. Model..
[44] P. Malherbe,et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. , 2003, Molecular pharmacology.
[45] K. Jacobson,et al. Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor* , 2002, The Journal of Biological Chemistry.
[46] D. Rognan,et al. Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.
[47] Paul D Lyne,et al. Structure-based virtual screening: an overview. , 2002, Drug discovery today.
[48] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[49] David Alagille,et al. Functionalization at position 3 of the phenyl ring of the potent mGluR5 noncompetitive antagonists MPEP. , 2005, Bioorganic & medicinal chemistry letters.
[50] Nagarajan Vaidehi,et al. First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin. , 2004, Biophysical journal.
[51] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[52] Karolina Nilsson,et al. Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. , 2006, Bioorganic & medicinal chemistry letters.
[53] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[54] Didier Rognan,et al. Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain* , 2004, Journal of Biological Chemistry.
[55] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[56] N. Cosford,et al. Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodology. , 2004, Bioorganic & medicinal chemistry letters.
[57] Ilya Pyatkin,et al. Positive and negative modulation of group I metabotropic glutamate receptors. , 2008, Journal of medicinal chemistry.
[58] Martin Stahl,et al. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP , 2006, Journal of neurochemistry.
[59] Didier Rognan,et al. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.
[60] Z. Deng,et al. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.
[61] Gisbert Schneider,et al. Scaffold‐Hopping: How Far Can You Jump? , 2006 .
[62] Mark Washburn,et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.
[63] Eric J Martin,et al. Target-biased scoring approaches and expert systems in structure-based virtual screening. , 2004, Current opinion in chemical biology.
[64] Qiang Zhang,et al. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. , 2006, Journal of medicinal chemistry.
[65] Tom L. Blundell,et al. Keynote review: Structural biology and drug discovery , 2005 .
[66] Eckart Bindewald,et al. A scoring function for docking ligands to low‐resolution protein structures , 2005, J. Comput. Chem..
[67] G. Schneider,et al. Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts , 2006, ChemMedChem.
[68] H. Gohlke,et al. Improving binding mode predictions by docking into protein-specifically adapted potential fields. , 2005, Journal of medicinal chemistry.
[69] Maya Topf,et al. PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.
[70] Ricardo L. Mancera,et al. Expanded Interaction Fingerprint Method for Analyzing Ligand Binding Modes in Docking and Structure-Based Drug Design , 2004, J. Chem. Inf. Model..
[71] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[72] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[73] G. Klebe,et al. Approaches to the Description and Prediction of the Binding Affinity of Small-Molecule Ligands to Macromolecular Receptors , 2002 .
[74] Karolina Nilsson,et al. Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues. , 2006, Bioorganic & medicinal chemistry letters.
[75] Fabian Mörchen,et al. Maximum Common Binding Modes (MCBM): Consensus Docking Scoring Using Multiple Ligand Information and Interaction Fingerprints , 2008, J. Chem. Inf. Model..
[76] J. Ballesteros,et al. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.
[77] G. Schneider,et al. Virtual Screening for Selective Allosteric mGluR1 Antagonists and Structure–Activity Relationship Investigations for Coumarine Derivatives , 2007, ChemMedChem.
[78] D C Teller,et al. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). , 2001, Biochemistry.
[79] G. Klebe,et al. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. , 2003, Journal of molecular biology.
[80] I. Gantz,et al. Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor)* , 1997, The Journal of Biological Chemistry.
[81] Robert P Sheridan,et al. Chemical similarity searches: when is complexity justified? , 2007, Expert opinion on drug discovery.
[82] T. Klabunde,et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.
[83] B. Shoichet,et al. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. , 2003, Journal of medicinal chemistry.
[84] T. Kamenecka,et al. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.
[85] G. Schneider,et al. New Allosteric Modulators of Metabotropic Glutamate Receptor 5 (mGluR5) Found by Ligand‐Based Virtual Screening , 2005, Chembiochem : a European journal of chemical biology.
[86] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[87] P. Hajduk,et al. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. , 1999, Journal of medicinal chemistry.
[88] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[89] S. Betz,et al. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. , 2006, Journal of medicinal chemistry.
[90] D R Flower,et al. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists. , 1999, Journal of medicinal chemistry.
[91] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[92] Dehua Huang,et al. 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. , 2004, Bioorganic & medicinal chemistry letters.
[93] B. Muñoz,et al. Discovery of novel modulators of metabotropic glutamate receptor subtype-5. , 2004, Bioorganic & medicinal chemistry.